Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: A DNA microarray study  by Schomisch, Steve J. et al.
Schomisch et al Cardiopulmonary Support and PhysiologyCardioplegia prevents ischemia-induced transcriptional
alterations of cytoprotective genes in rat hearts: A DNA
microarray study
Steve J. Schomisch, BS,a Deborah G. Murdock, PhD,b Nasim Hedayati, MD,a Joseph L. Carino, BS,aEdward J. Lesnefsky, MD,c and Brian L. Cmolik, MDd
CS
PFrom the Division of Cardiothoracic Sur-
gery, Case Western Reserve University,
University Hospitals of Cleveland,a Cleve-
land, Ohio; the Department of Pediatrics,
Vanderbilt University,b Nashville, Tenn;
the Cardiology Section, Medical Service,
Louis Stokes Department of Veterans Af-
fairs Hospital and Case Western Reserve
University,c Cleveland, Ohio; and the Divi-
sion of Cardiothoracic Surgery, Louis
Stokes Department of Veterans Affairs
Hospital, Case Western Reserve Univer-
sity, University Hospitals of Cleveland,d
Cleveland, Ohio.
Supported by the Jay L. Ankeney Endow-
ment. Dr Lesnefsky was supported by
grants 2RO1AG12447 and 1PO15885 from
the National Institutes of Health and by the
Medical Research Service, Department of
Veterans Affairs. Dr Hedayati was an Allen
Fellow supported by the Jay L. Ankeney
Professorship in Cardiothoracic Surgery,
Case Western Reserve University School of
Medicine, Cleveland, Ohio.
Received for publication March 3, 2005;
revisions received May 25, 2005; accepted
for publication June 8, 2005.
Address for reprints: Brian L. Cmolik, MD,
Cardiothoracic Surgery, University Hospi-
tals of Cleveland, 11100 Euclid Ave,
Cleveland, OH 44106-5011 (E-mail:
blc3@case.edu).
J Thorac Cardiovasc Surg 2005;130:1151-8
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.06.027
TheBackground: Energy conservation and calcium homeostasis contribute to myocar-
dial protection provided by hyperkalemic cardioplegia during ischemia. Compli-
menting these established mechanisms of protection, previous work suggested that
activation of cytoprotective signaling pathways also contributes to reduced injury
with cardioplegia. We proposed that cardioplegia would recruit cytoprotec-
tive pathways and investigated the transcriptional response of the heart after
cardioplegia-protected ischemia compared with that after ischemia alone.
Methods: Isolated perfused rat hearts underwent 40 minutes of global ischemia
alone or with St Thomas cardioplegia, followed by 120 minutes of reperfusion. The
expression profiles of isolated RNA were determined by using Affymetrix microar-
rays and assessed by comparing cardioplegia-protected hearts and hearts undergoing
unprotected ischemia with time-matched control hearts. The content of selected
proteins was assessed by means of immunoblotting.
Results: Cardioplegia preserved the expression of multiple genes involved in car-
bohydrate and fatty acid metabolism, glycolysis, and electron transport compared
with ischemia alone. The expression of the sodium-calcium exchanger and ryano-
dine receptor was preserved in line with the ability of cardioplegia to decrease
calcium overload. The expression of multiple cytoprotective molecules, including
protein-tyrosine kinase, calcineurin B, p38 mitogen-activated protein kinase,
voltage-dependent anion channel, protein kinase C , heat shock protein 70, and
manganese superoxide dismutase all showed decreased expression in ischemia but
were preserved to near nonischemic levels by cardioplegia.
Conclusion: Cardioplegia during ischemia maintained an expression profile similar
to that seen in nonischemic hearts for genes involved in energy conservation,
calcium homeostasis, and cytoprotective pathways, whereas ischemia alone did not.
Exposing the transcriptional differences in cytoprotective genes during untreated
and cardioplegia-treated ischemia provides valuable insight into an additional mech-
anism of cardioprotection induced by cardioplegia.
Cardioplegic arrest is used to provide myocardial protection in the majority ofthe 686,000 patients who undergo cardiac surgical procedures in the UnitedStates each year.1 The arrested heart, although advantageous to the surgeon,
remains susceptible to ischemic injury. Hyperkalemic cardioplegia (CP) is used to
maintain diastolic arrest and provide myocardial protection by attenuating the
progression of ischemic injury. Despite modifications to the formulation and route
of administration, suboptimal myocardial protection remains a problem. The pro-
tective effect of CP is thought to be largely the result of conservation of cellular
energy stores and preservation of calcium homeostasis. In addition to these accepted
mechanisms of myocardial protection, previous work from our laboratory demon-
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substantially attenuated if intracellular signaling pathways
involving protein kinase C (PKC) or tyrosine kinase are
inhibited.2 Activation of these signaling kinases leads to
cytoprotection and has been implicated in the robust car-
dioprotective response of ischemic preconditioning (IPC).
This evolving appreciation of the key contribution of the
activation of intracellular signaling pathways to myocardial
protection3 raises the question of whether similar mecha-
nisms might contribute to the cardioprotection provided by
CP. To identify potential key contributing mechanisms in-
volved in the cardioprotection of CP, we used DNA mi-
croarray technology to profile the gene expression pattern of
rat hearts subjected to ischemia and reperfusion alone com-
pared with that seen in hearts subjected to CP-protected
ischemia and reperfusion. The goal of this study was to
evaluate transcriptional changes in genes related to previ-
ously known mechanisms of CP and to assess for evidence
of the novel involvement of cytoprotective pathways.
Materials and Methods
All experiments were approved by the Case Western Reserve
University Institutional Animal Care and Use Committee and
conformed to the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal Re-
sources, National Research Council and published by the National
Academy Press (revised 1996).
Isolated Rat Heart Preparation
The isolated rat heart preparation was used as previously de-
scribed.2 Male Sprague-Dawley rats (320-360 g) were anesthetized
(heparin, 1000 units/kg administered intraperitoneally; pentobar-
bital, 100 mg/kg administered intraperitoneally). Hearts were ex-
cised, mounted on the Langendorff apparatus, and perfused with
Krebs-Henseleit (KH) buffer delivered at a perfusion pressure of
65 mm Hg. After collection of baseline data during the equilibra-
tion period, the hearts were randomized into one of the 3 study
groups. Time-matched control hearts (n  7) were perfused for
180 minutes. Hearts in the ischemic group (n  7) were equili-
brated for 20 minutes and then underwent 40 minutes of normo-
thermic global ischemia, followed by 120 minutes of reperfusion
with KH buffer. Hearts in the CP group (n  7) were equilibrated
for 17 minutes, perfused with St Thomas’ Cardioplegia II (NaCl,
110.0 mmol/L; KCl, 16.0 mmol/L; CaCl2, 1.20 mmol/L;
MgCl2*6H2O, 16.0 mmol/L; and NaHCO3, 10.0 mmol/L; pH of
7.8  0.2, T  4°C) for 3 minutes, and underwent 40 minutes of
normothermic global ischemia, followed by 120 minutes of reper-
fusion with KH buffer. After 180 minutes, left ventricular (LV)
tissue was excised and immediately frozen in liquid nitrogen.
Three hearts from each group were used for RNA preparation, and
4 hearts were used independently for protein quantitation.
Microarray Analysis
Samples of total RNA were processed by the Gene Expression
Array Core Facility at Case Western Reserve University.
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using Trizol Reagent (Invitrogen). RNA preparations from each
group (ischemic, CP, and control) were pooled (n  3), and their
quality and quantity (0.79, 0.91, and 1.10 g RNA/mg LV tissue)
were assessed with spectrophotometry (260/280) and gel electro-
phoresis. Samples were cleaned and eluted by using a column from
a Qiagen RNeasy kit (part no. 74106) precipitated with ammonium
acetate and ethanol centrifuged, washed, and resuspended.
Synthesis of cDNA. The Affymetrix protocol for cDNA syn-
thesis was used. The reaction was primed by annealing an oligo-dT
primer coupled to a T7 RNA polymerase promoter to the RNA
sample. RNA was reverse transcribed with Superscript II reverse
transcriptase. Second-strand synthesis was carried out immediately
in the presence of Escherichia coli DNA pol I, RNAse H, and
DNA ligase; incubated in the presence of T4 DNA pol; and
terminated with ethylenediamine tetraacetic acid (EDTA). The
sample was cleaned (Qiagen cDNA clean-up column).
Synthesis of biotin-labeled complementary RNA. Comple-
mentary RNA was generated in an in vitro transcription reaction
by using a BioArray High Yield ENZO kit (Affymetrix). Samples
were mixed, centrifuged, and returned to the incubator every 40
minutes. In vitro transcription samples were cleaned (Qiagen RNA
clean-up columns) and eluted. The quality was confirmed spectro-
photometrically (260/280).
Fragmentation and hybridization to test array. Samples were
fragmented (40 mmol/L Tris acetate [pH 8.1], 100 mmol/L potas-
sium acetate, and 30 mmol/L magnesium acetate at 94°C for 35
minutes) and added to hybridization buffer (final concentrations:
100 mmol/L morpholinoethanesulfonic acid (MES); 1 mol/L
[Na]; 20 mmol/L EDTA; 0.01% Tween 20; 0.1 mg/mL Herring
sperm DNA; and 0.5 mg/mL acetylated bovine serum albumin) to
improve hybridization to the oligonucleotide array. Eukaryotic
hybridization controls (BioB, BioC, BioD, and cre; final concen-
trations of 1.5, 5, 25, and 100 pmol/L, respectively) and control
oligonucleotide (50 pmol/L) were added to the cocktail. The hy-
bridization cocktail was denatured (99°C for 5 minutes), trans-
ferred to the test array, and incubated (42°C for 16 hours), and the
hybridization cocktail was removed. The array was washed,
stained, and scanned for background fluorescence and expression
levels of control oligonucleotides by using Affymetrix Microarray
Suite software.
Hybridization of fragmented samples to species microarray.
Sample hybridization cocktails were thawed (45°C) and centri-
fuged. The Affymetrix chip arrays (RG-U34A, part no. 510338),
containing probe sets for more than 7000 known genes, were
equilibrated to room temperature. Sample cocktails were intro-
duced into the chamber of the preconditioned chips and incubated
(45°C for 16 hours). The chips were washed, stained, and scanned
with an Agilent Gene Array scanner 2000 driven by Affymetrix
MicroArray Suite 5.0. Genes with unknown products or duplicate
entries were omitted. Functional or biologic classification was
determined from the Affymetrix database, the PubMed database,
or both.
Statistical analysis of species microarray. Scanned images
were analyzed with Affymetrix MAS 5.0 software. For complete
description of the statistical algorithms, refer to the Statistical
Algorithm Description Document available from Affymetrix. The
following tunable parameters were used: 1  0.04 and  2 
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 0.0025, 2L  0.003, and 2H  0.003 for comparison anal-
ysis. Statistical significance is determined by query of 3 parame-
ters: detection, fold change, and change. To be regarded as in-
creased in the treated sample compared with the control, detection
was “P” (present) or “M” (marginal), fold change was 2 or more,
and change was “I” (increased). For decreases, detection in the
sample was “P” or “M,” fold change was 2 or less, and change
was D (decreased). The change algorithm uses the Wilcoxon
signed-rank test with corresponding cutoffs of  (P  .0025 vs
control).
Western Analysis
Frozen ventricular tissue was placed in buffer (Tris-HCl, 50
mmol/L [pH 7.4]; sodium orthovanadate, 0.1 mmol/L; sodium
fluoride, 50 mmol/L; sucrose, 150 mmol/L; phenylmethylsulfonyl
fluoride, 1 mmol/L; EDTA, 5 mmol/L; ethyleneglycol-bis-(-
aminoethylether)-N,N,N=,N=tetraacetic acid, 2 mmol/L; 0.2% Tri-
ton X-100, Sigma protease inhibitor cocktail 1:200 [producing
final concentrations of 4-(2-aminoethyl)benzenesulfonylfluoride
HCl (AEBSF), 500 mol/L; Aprotinin, 0.4 mol/L; Leupeptin, 10
mol/L; Bestatin, 18 mol/L; Pepstatin, 7.5 mol/L; E-64, 7
mol/L]) and homogenized (Polytron, 2 bursts of 30 seconds,
speed 5). The lysate was mixed on ice for 60 minutes. The
solubilized proteins were centrifuged at 360g for 10 minutes, and
the resulting supernatant was assayed for total protein concentra-
tion by using the Bradford method. Total protein (15 g) was
separated by means of sodium dodecylsulfate–polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride mem-
brane. Nonspecific binding was blocked with 5% nonfat milk, and
the membrane was incubated with primary antibody (anti-p38,
mouse monoclonal sc-7972, Santa Cruz Biotechnology Inc; anti–
protein-tyrosine kinase [anti-JAK2], rabbit polyclonal, Upstate
Biotechnology; anti–sodium-calcium exchanger, rabbit polyclonal,
Swant). The membrane was washed and incubated with the ap-
propriate horseradish peroxidase–linked secondary antibody,
washed, and then incubated with a chemiluminescent agent (Lu-
minol, Santa Cruz Biotechnology). Photographic film was exposed
to the chemiluminescence, and the bands were quantified by means
of densitometry (Scion Image, Scion Corp) as normalized to a
control lysate.
Statistical Analysis of Left Ventricular Developed
Pressure Recovery, Lactate Dehydrogenase Release,
and Protein Content
Data are expressed as means  SEM. One-way analysis of vari-
ance with the Tukey post-hoc test were performed on left ventric-
ular developed pressure (LVDP) recovery, lactate dehydrogenase
(LDH) release, and protein content.
Results
LVDP and LDH
Time-matched control hearts performed as expected for this
model, with preserved LVDP after 180 minutes. Ischemic
hearts showed decreased recovery of function compared
with control hearts. CP treatment before ischemia markedly
protected against the decrease in LVDP (Figure 1). Ischemic
The Journal of Thoracic anhearts showed a significant increase in LDH release com-
pared with that seen in nonischemic control hearts, as well
as compared with hearts undergoing CP-treated ischemia
(Figure 1). Values for LVDP and LDH release are compa-
rable with those obtained previously in this model.2
Expression Profile
The gene expression profile of rat hearts subjected to CP-
protected ischemia and reperfusion was compared with the
profile in hearts subjected to ischemia and reperfusion alone
and with the time control group. The number of genes with
2-fold or greater change was reduced by removing probes
with unknown products and duplicates (multiple probe sets
Figure 1. Recovery of function (top) at 180 minutes and LDH
release during minutes 60 through 90. LVDP, Left ventricular
developed pressure; LDH, lactate dehydrogenase. *P < .001 ver-
sus control or cardioplegia groups.that hybridize to the same product). After this reduction,
d Cardiovascular Surgery ● Volume 130, Number 4 1151.e3
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the unprotected ischemic group that was unchanged in the
CP-protected ischemic group compared with the nonis-
chemic control group. With the same 2-fold cutoff point, 18
differences were found to be unique to the CP-treated group
but not to the ischemia group compared with the control
group. Thirty-three genes demonstrated 2-fold or greater
change in both the ischemia and CP-treated groups com-
pared with the control group. Most of the changes unique to
the ischemic group demonstrated decreased expression
(112/146), whereas changes unique to CP treatment pre-
dominantly reflected increased expression (11/18).
Genes with increased expression in the ischemic group
but not in the CP-treated group represent products that
display a diverse array of functions (Table E1) and include
some potentially related to cardioprotection. Among the
TABLE 1. Biologic function of genes with decreased ex-
pression after ischemia but preserved with cardioplegia
No. of genes Function/description
Energy/metabolism
2 Acetyl CoA synthesis from pyruvate
1 ATP metabolism
7 Carbohydrate metabolism
5 Electron transport/energy production
7 FA metabolism
7 Other
Calcium regulation
2 Calcium regulation
1 Calcium channel binding
2 Calcium binding
Immune/inflammatory
4 Immune/inflammatory
Cytoprotective-ischemia/IPC/stress
4 Stress response
3 Glutathione synthesis/oxidative
stress
3 Heat shock/chaperone
2 Oxidative stress
5 Other
Transcription
11 Transcription
Other
9 Protein transport
4 Adhesion molecule
4 Angiogenesis
4 Cytoskeletal
2 Mg2-dependent phosphatase
3 Growth
2 Cell cycle
19 Other
A complete list is available online in Table E2. CoA, Coenzyme A; ATP,
adenosine triphosphate; FA, fatty acid; IPC, ischemic preconditioning.genes exhibiting decreased expression after ischemia but
1151.e4 The Journal of Thoracic and Cardiovascular Surgery ● Othat were not diminished with CP protection (Tables 1 and
E2) are 29 genes involved in carbohydrate metabolism, fatty
acid metabolism, glycolysis, electron transport, or other
cellular processes involved in energy production. Five
genes involved in calcium regulation or calcium binding,
including the sodium-calcium exchanger (NCx) and ryano-
dine receptor, had decreased expression after ischemia un-
less protected with CP. Genes for proteins involved in
cytoprotection, including JAK2, calcineurin B, p38
mitogen-activated protein kinase (MAPK), voltage-depen-
dent anion channel, PKC-binding protein enigma, PKC-,
heat shock protein 70–related gene and precursor, and mi-
tochondrial manganese superoxide dismutase, also did not
maintain baseline levels of their transcripts after ischemia
unless first protected with CP.
Genes exhibiting decreased expression in both the isch-
emia and CP-treated groups were predominantly those that
function in the inflammatory or immune responses, notably
tumor necrosis factor  and interleukin 1 (Table E3). The
genes with increased expression after ischemia in both the
untreated and CP-treated groups compared with the control
group were few and included heat shock protein 70 (Table
E3).
Of the few genes altered by CP-protected ischemia, 3
related to the immune-inflammatory response, including
interleukin 18, demonstrated decreased expression (Table
2). Genes with increased expression in CP treatment but not
ischemia displayed seemingly diverse functions, with the
largest change being an increase in a heat shock protein
(Table 2).
Content of Selected Proteins
Protein content was evaluated by means of Western analysis
and compared with transcript levels to validate selected
results observed at the level of gene translation. Western
analysis revealed a significantly reduced content of p38
MAPK in untreated ischemic hearts compared with either
control (P  .001) or CP-treated hearts (P  .001, Figure
2). The protein content of JAK2 was also reduced in isch-
emic hearts compared with control hearts (P  .009) or
hearts undergoing CP-treated ischemia (P  .019). Differ-
ences between groups in NCx protein content, however,
were not significant (data not shown).
Discussion
This study was designed to investigate potential mecha-
nisms whereby CP provides myocardial protection by eval-
uating changes that occur at the level of transcription. Rel-
ative transcript abundance was evaluated by using the
microarray approach. The alterations in gene expression
caused by ischemia alone or ischemia protected with CP
was assessed in isolated rat hearts perfused by means of the
Langendorff method.
ctober 2005
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normothermic global ischemia, eliminates the confounding
effects of hypothermic ischemia and was shown to provide
good resolution between treatments in functional end points
(Figure 1).2 Microarray analysis in the 3 groups revealed
differences corroborating the known protective mechanisms
of CP, namely energy conservation and calcium homeosta-
sis. The transcriptional data also support the preservation of
a nonischemic phenotype by cardioplegia, a new
observation.
It is important to recall that although collectively isch-
emia is damaging to cardiac function, the changes in the
expression of individual genes is not necessarily detrimen-
tal. Likewise, although CP protection improves function,
each of the changes in individual gene expression levels is
not necessarily beneficial. The stimulus of ischemia or CP
might evoke a combination of responses activating adaptive
or protective mechanisms, as well as disrupting normal cell
functions. A comparison of gene expression levels between
ischemia and CP-protected ischemia therefore might pro-
vide clues as to the mechanism of cardioprotection, as well
as its limitations. Additionally, gene expression studies are
not definitive but are rather preliminary studies to focus
further investigation.
The greatest disruption to the normal transcription pro-
cess occurred in the untreated ischemic group, with 133
TABLE 2. Changed expression with cardioplegia but not i
Gene no. Ischemia vs C CP vs C
Immune-inflammatory
U65217 1.2 3.5 MHC
U77777 NC 2.1 Inter
X54250 1.9 2.0 HIV
Cytoprotective-ischemia/IPC/stress
U53922 1.7 2.3 DnaJ
AA108277 1.5 5.7 simil
Transcription
L20681 NC 2.0 ETS-
D26307 1.7 2.1 jun-D
Other
D12769 1.6 2.1 Krup
X06769 1.9 2.3 c-fos
U75397 1.9 2.3 Krox
AF034899 NC 2.5 Olfac
AF063102 1.2 2.3 CIRL
D10757 1.5 2.3 Prote
L35558 1.7 2.1 Gluta
U49099 1.9 2.0 Cis-G
M94918 1.7 2.0 Hem
Y13275 NC 2.0 Tran
AF030088 NC 2.0 Hom
Values represent fold change. Negative designates decrease. C, Control; C
calcium-independent receptor of alpha-latrotoxin-2.genes demonstrating a 2-fold or greater decrease in expres-
The Journal of Thoracic ansion. CP treatment limited the decreased transcript content
to merely 28 genes. The ability of CP treatment to maintain
expression levels nearer to control for genes otherwise
altered by ischemia suggests that CP, in general, preserves
a nonischemic transcriptional profile and is likely to main-
tain a nonischemic phenotype. The protein content data
shown in Figure 2 support this notion.
The ability of CP treatment to maintain transcription
levels of genes involved in carbohydrate metabolism, fatty
acid metabolism, glycolysis, electron transport, and calcium
homeostasis suggests mechanisms of CP involving the rel-
ative conservation of energy and prevention of cellular
calcium overload. The NCx and ryanodine receptor are
important regulators of Ca2 homeostasis. Increased ex-
pression of NCx and ryanodine receptor has been demon-
strated as an adaptive response to low-flow ischemia.4 Al-
though we were unable to demonstrate differences in the
protein content for NCx, here we show increased gene
expression in CP-protected ischemia compared with that in
ischemia alone for these important regulators of calcium
homeostasis.
Assessing the changes that occur to gene expression by
cardioplegia protection but not by ischemia alone (Table 2)
arguably would appear most pertinent to the mechanism of
cardioplegia. Surprisingly, this category contained rela-
tively few genes. Furthermore, the magnitude of change was
mia
Gene product Function-description
s II antigen RT1.B beta Immune/inflammatory
n 18 Immune/inflammatory
I enhancer-binding protein 1 Immune/inflammatory
protein (RDJ1) Heat shock/chaperone
Heat shock protein (hsp-E7I) Heat shock/chaperone
to-oncogene Transcription
Transcription
ke factor 9 Growth and development
Growth and development
Growth and development
receptor-like (SCR D-9) Chemoreceptor
-Latrotoxin receptor
e subunit, -9 Protein catabolism
/aspartate transporter Glutamate signaling
p28 (p28) Protein transport
in beta chain Oxygen transport
brane 4 family member 3 Blood coagulation
Glutamate signaling
rdioplegia; MHC, major histocompatibility complex; NC, no change; CIRL-2,sche
clas
leuki
type
-like
ar to
1 pro
pel-li
-24
tory
-2
asom
mate
olgi
oglob
smem
er
P, casmall, with just one gene exhibiting greater than a 3-fold
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finding refutes our hypothesis that cardioplegia would acti-
vate numerous cytoprotective pathways but rather suggests
that the cardioprotection of cardioplegia might be less a
Figure 2. Myocardial abundance of p38 mitogen-activated protein
kinase (p38, top) and protein-tyrosine kinase (JAK2, bottom) in
time-matched control (open bar), ischemic (hatched bar), or car-
dioplegia-treated (filled bar) hearts after 2 hours of reperfusion or
equivalent time for control hearts (n  4). Units are relative to a
common, nonischemic heart value set at 1.00. Western blotting
shows representative hearts (n  2) for each group. *P < .05
compared with control or cardioplegia-treated hearts.factor of transcriptional changes induced by the treatment
1151.e6 The Journal of Thoracic and Cardiovascular Surgery ● Oand more a function of minimizing ischemia-induced alter-
ations in transcription.
Of particular focus in this study were changes in genes
known to be involved in cytoprotective mechanisms, in-
cluding IPC. As with other cluster groups, CP-protected
ischemia produced expression levels closer to baseline lev-
els than did unprotected ischemia for genes related to cyto-
protective pathways (Figure 3). Interestingly, several genes
with decreased expression in ischemia but preserved with
CP treatment have previously been shown to have roles in
the cardioprotective response during ischemia and reperfu-
sion (Tables 1 and E2). These include JAK2,6 calcineurin
B,7,8 p38 MAPK,9 voltage-dependent anion channel,3 PKC-
binding protein enigma,10 PKC-,11 heat shock protein 70 –
related gene and precursor,12 and manganese superoxide
dismutase.13 Although the precise role for each of these
gene products is unclear, the evidence implicating them in
ischemia or cardioprotective mechanisms makes the alter-
ations observed in our study intriguing. Repressed gene
Figure 3. Cardioplegia preserves expression of genes with cyto-
protective function. Open bars represent unprotected ischemia,
and filled bars represent cardioplegia-protected ischemia. Data
are displayed relative to control values of 1, such that a 2-fold
decrease (2) is equivalent to 0.5. HSP70, 70-kd Heat shock
protein; KATP-1, adenosine triphosphate–sensitive potassium
channel uKATP-1; MAPK P-1, mitogen-activated protein kinase
phosphatase 1; HSP70 precursor, 70-kd heat shock protein pre-
cursor; MAP3K8, serine-threonine protein kinase (Map3k8);
PKC-e, protein kinase C ; MnSOD, manganese superoxide dis-
mutase; Heme Ox, heme oxygenase; HSP-related (hst70), heat
shock protein-related gene hst70; SCS-3, suppressor of cytokine
signaling 3; VDAC, voltage-dependent anion channel; p38 MAPK,
p38 mitogen-activated protein kinase; JAK2, protein-tyrosine
kinase.expression of these mediators after ischemia, as we have
ctober 2005
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the cell’s inability to maintain appropriate content of these
peptides and thus contribute to injury. The ability of the
CP-protected heart to maintain expression levels much
closer to the baseline levels suggests mechanisms of
cardioplegia-induced protection that were previously
unknown.
Genes with increased expression in ischemia but not CP
compared with control values (Table E1) included the aden-
osine triphosphate–sensitive potassium channel and MAPK
phosphatase 1, proteins involved in modulation of cardiac
injury during ischemia. Once thought to be the final step in
the signaling cascade of IPC,5 the opening of mitochondrial
adenosine triphosphate–sensitive potassium channels is one
of many important alterations in mitochondrial proteins that
might contribute to cardioprotection.3 Exactly which mem-
bers of the MAPK cascades are involved and how they
function remains unclear. However, much evidence sup-
ports their involvement in the cardioprotection of IPC.3,5
Increased expression after ischemia of proteins related to
these mechanisms could be indicative of a response by the
cell to upregulate their production in an attempt to attenuate
ischemic damage. If this upregulation is beneficial and yet
deficient in the CP-treated group, this finding might provide
an opportunity to improve the protection provided by CP.
To validate the transcriptional changes for select genes and
to assess the potential physiologic effect, we quantified 3
proteins of interest. The protein content of p38 MAPK and
JAK2 correlated with the observed change in transcription
(Figure 2). The smaller change in transcript levels of NCx
was not reflected in protein content (data not shown). Fur-
ther characterization of these changes by measuring abun-
dance of specific transcripts and protein activity might be
beneficial to determine their role in cardioprotection.
Also noteworthy is the disproportionate number of genes
involved in the inflammatory response, which displayed
decreased expression in ischemia and CP (Table E3). Rec-
ognizing the relationship of ischemia to oxidative stress and
of the latter to inflammation, we anticipated increased ex-
pression for many inflammatory markers in the ischemic
group but not in the CP group. Perhaps this represents the
extent of dysfunction caused in ischemia and in CP treat-
ment before ischemia or occurs because of the use of the
buffer-perfused heart as the model of experimental isch-
emia. This finding nonetheless suggests that the heightened
inflammatory response prevalent after cardiopulmonary by-
pass (CPB) might not occur as a result of CP but rather is
activated by other factors. The unique expression profile in
human atrial tissue after CPB and cardioplegic arrest14
provides valuable data to support this statement. These
investigators noted increased expression of inflammatory
genes after CPB. Our observation of predominantly de-
creased inflammatory genes in the isolated perfused heart
The Journal of Thoracic ansuggests that the increases observed in the clinical setting
might occur because of one or more of the additional factors
associated with the clinical cardiac surgical setting, includ-
ing perhaps the CPB circuit, hypothermia, surgical trauma,
anesthesia, or preexisting ischemia. Additionally, induced
genes unique to the clinical study might be reflective of
differences between analysis of LV tissue from an isolated
rat heart and atrial tissue from CPB surgery or merely
limitations of the microarray technique. Future studies will
be needed to delineate these differences.
The current study evaluated differences in the gene ex-
pression pattern between hearts subjected to ischemia alone
or hearts protected with hyperkalemic CP before ischemia.
Ischemia altered the pattern of expression to a much greater
extent in untreated hearts than in hearts first protected with
CP, suggesting that CP-protected ischemia tends to preserve
the nonischemic transcriptional phenotype. Many of the
genes exhibiting decreased expression caused by ischemia
alone are important in energy production and calcium ho-
meostasis, which is consistent with proposed mechanisms
of CP-induced myocardial protection. In addition, the car-
dioprotection provided by CP maintains cytoprotective pep-
tides reminiscent of IPC. The novel concept that cardiople-
gia can prevent ischemic disruptions to the transcriptional
processes of many genes, including those involved in cyto-
protection, is worthy of consideration for advancing myo-
cardial protective strategies during cardiac surgery.
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ecreted Protein Acidic and Rich in Cysteine.
Schomisch et al Cardiopulmonary Support and PhysiologyTABLE E1. Increased expression with ischemia but uncha
Gene no.
Ischemia
vs C CP vs C
Energy/metabolism
D16102 5.7 NC ATP-stim
transl pr
M33648 2.6 NC 3-Hydrox
synthase
U07971 2.5 1.7 L-Arginin
S69874 2.1 NC Cutaneo
X51529 2.0 NC Platelet
L46791 2.5 NC Choleste
Calcium regulation/contractility
D29646 2.0 NC ADP-ribo
X52840 2.3 NC Myosin
Immune/Inflammatory
L23128 2.1 1.7 MHC cla
M64986 2.0 1.2 Amphote
Cytoprotective-ischemia/IPC/stress
D42145 3.0 1.5 ATP-sen
uKATP-1
S81478 2.6 NC MAP kin
L01702 2.6 1.6 Protein-
K01932 2.1 NC glutathio
Transcription
Z17223 3.0 1.9 Gax pro
AF000942 2.6 1.4 Id3a
X61296 2.5 NC L1 retrop
U17254 2.5 NC Immedia
factor N
U91679 2.1 NC ETS dom
Other
X59859 2.3 NC decorin
Y13714 2.0 NC osteone
U75928 2.0 1.3 SPARC
J04035 2.0 1.4 Tropoela
X55183 2.8 1.9 Schwan
M81183 2.3 1.4 Insulin-l
M31837 2.0 NC Insulin-l
protein (
J05495 2.5 1.6 Gal/GalN
U82623 3.0 NC RalA bin
M96601 2.3 NC Taurine
D14014 2.3 NC Cyclin D
X71127 2.1 1.3 Complem
V01227 2.0 1.4 -Tubuli
U42627 2.0 NC Dual-spe
phospha
X12957 2.6 NC  Crysta
Values are fold changes. C, Control; CP, cardioplegia; NC, no change; AT
diphosphate; MHC, major histocompatibility complex; IPC, ischemic preco
reading frame 2; NGFI-B, nerve growth factor–induced clone B; SPARC, Snged with cardioplegia
Gene product Function/description
ulated glucocorticoid-receptor
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Carbohydrate metabolism
y-3-methylglutaryl-CoA Acetyl CoA metabolism
e-glycine amidinotransferase Amino acid metabolism
us fatty acid-binding protein FA metabolism
phospholipase A2 FA metabolism
rol esterase Carboxylesterase activity
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rin Immune/inflammatory
sitive potassium channel Stress/IPC/cardioprotection
ase phosphatase 1 Stress induced
tryosine-phosphatase (LRP) PKC-dependent Src act
ne S-transferase Yc subunit Glutathione synthesis/stress
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Transcription
oson, ORF2 Transcription
te early gene transcription
GFI-B
Transcription
ain transcription factor Pet-1 Transcription
Extracellular matrix org
ctin Extracellular matrix org
Extracellular matrix org
stin Extracellular matrix org
noma-derived growth factor Growth factor
ike growth factor I Growth factor
ike growth factor-binding
IGF-BP3)
Growth factor
Ac-specific lectin Binds to Gal/GalNAc
ding protein 1 Protein transport
transporter Neuroprotective
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ent protein C1q -chain Complement activation
n Microtubule movement
cificity protein tyrosine
tase (rVH6)
Phosphatase
llin gene cluster Eye lens proteins
P, adenosine triphosphate; CoA, coenzyme A; FA, fatty acid; ADP, adenosine
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Gene no.
Ischemia
vs C CP vs C Gene product Function/description
Energy/metabolism
AF034577 3.7 NC Pyruvate dehydrogenase kinase (PDK4) Acetyl CoA synthesis from pyruvate
Z12158 3 NC PDH E1  form 1 subunit Acetyl CoA synthesis from pyruvate
D13376 2.5 1.3 Adenylate kinase 1 ATP metabolism
M27726 4.9 NC Phosphorylase (B-GP1) Carbohydrate metabolism
U20643 4 1.3 Aldolase A Carbohydrate metabolism
AFFX-h 3.5 NC Brain hexokinase Carbohydrate metabolism
D26393 3.5 1.6 Type II hexokinase Carbohydrate metabolism
U20195 3.2 NC Phosphoglucomutase (Pgm1) Carbohydrate metabolism
M93401 2.1 NC Methylmalonate semialdehyde DH Carbohydrate metabolism
S50461 2.1 NC G protein  12 subunit Carbohydrate metabolism
D10952 3.5 NC Cytochrome c oxidase subunit Vb Electron transport/energy
production
AA686031 3.5 NC Like NADH-ubiquinone oxidoreductase 75 Electron transport/energy
production
M21476 2.5 NC Iodothyronine 5-monodeiodinase (5-MD) Electron transport/energy
production
AA685112 2.5 NC Like NADH-ubiquinone oxidoreductase 23 Electron transport/energy
production
M24542 2.1 NC Rieske iron-sulfur protein Electron transport/energy
production
Y17295 3 NC 1-Cys peroxiredoxin FA metabolism
AB005743 2.8 NC CD36 antigen FA metabolism
AB010429 2.6 NC Acyl-CoA hydrolase-like protein FA metabolism
X98225 2.6 NC Gastrin-binding protein FA metabolism
AF047707 2.6 1.3 UDP-glucose:ceramide glycosyltransferase FA metabolism
AF063302 2.3 NC Carnitine palmitoyltransferase I FA metabolism
E03344 2.1 NC Peroxisome-forming factor FA metabolism
D44481 2.3 NC Crk II adaptor protein Glucose transport/adapter protein
D10853 2.3 NC Amidophosphoribosyltransferase Glutamine metabolism
L01793 2.3 NC Glycogenin Glycogen synthesis
D21869 2.6 NC Phosphofructokinase-M Glycolysis
J05571 2 NC S-adenosylmethionine synthetase Metabolism
M58364 2.3 1.9 GTP cyclohydrolase I Synthesis of cofactor BH4
AF034577 3.7 NC Pyruvate dehydrogenase kinase (PDK4) Acetyl CoA synthesis from pyruvate
Calcium regulation
X68191 3.5 NC Sodium-calcium exchanger Calcium regulation
U95157 2.5 NC Ryanodine receptor type II (RYR2) Calcium regulation
U48247 3.2 NC Protein kinase C–binding protein enigma Calcium channel binding
L18889 2.3 NC Calnexin Calcium binding
X53363 2.1 NC Calreticulin Calcium binding
Immune/inflammatory
U45965 3.5 1.9 Inflammatory protein-2 precursor Immune/inflammatory
X17053 3.0 1.9 Immediate-early serum-responsive JE gene Immune/inflammatory
M92340 2.0 1.2 Interleukin 6 signal transducer Immune/inflammatory
1151.e10 The Journal of Thoracic and Cardiovascular Surgery ● October 2005
Schomisch et al Cardiopulmonary Support and PhysiologyTABLE E2. continued
Gene no.
Ischemia
vs C CP vs C Gene product Function/description
AF029240 2.0 1.9 MHC class Ib RT1.S3 (RT1.S3) Immune/inflammatory
Cytoprotective-ischemia/IPC/stress
M94454 2.1 NC Serine-threonine protein kinase
(Map3k8)
Stress response
U13396 9.2 1.5 Protein-tyrosine kinase (JAK2) Stress response
U91847 7.5 NC p38 Mitogen-activated protein
kinase
Stress response
M18331 2.3 1.9 Protein kinase C  Stress response
J05181 7 1.4 -Glutamylcysteine synthetase Glutathione synthesis/oxidative
stress
X02904 2.3 1.4 Glutathione S-transferase P
subunit
Glutathione synthesis/oxidative
stress
J03914 2 1.3 Glutathione S-transferase Yb
subunit
Glutathione synthesis/oxidative
stress
X15705 2.8 NC Heat shock protein–related gene
hst70
Heat shock/chaperone
AA848268 2.3 NC Similar to DnaJ protein homolog 2 Heat shock/chaperone
S75280 2 NC 70-kd Heat shock protein
precursor
Heat shock/chaperone
Y00497 2.3 NC MnSoD Oxidative stress
U63923 2.3 NC Thioredoxin reductase Oxidative stress
D14568 8 NC Calcineurin B Ischemia
AF075383 2.8 NC Suppressor of cytokine signaling 3 Jak/STAT pathway
AJ005984 2.8 1.5 -Endosulfine K(ATP) channel regulation
AF048828 3.5 NC Voltage-dependent anion channel
(VDAC)
Mitochondrial calcium transport/IPC
J02722 2.5 NC Heme oxygenase Cleaves heme/stress induced
Transcription
M65251 3.5 1.9 Hivep2 Transcription
X54686 2.6 1.4 pJunB Transcription
X54249 2.5 1.6 Zinc finger protein AT-BP1 Transcription
M65149 2.3 1.7 CELF Transcription
D37951 2.3 1.5 MIBP1 (c-myc intron binding
protein 1)
Transcription
M55017 2.3 NC Nucleolin Transcription
X63369 2.3 1.5 Zinc finger protein Tis 11 Transcription
AF009330 2.0 NC SHARP-2 Transcription
L14462 2.0 NC R-esp1 Transcription
L14463 2.0 NC R-esp2 Transcription
U51584 2.0 NC Zinc finger enhancer–binding
protein 2
Transcription
Other
X53565 7.0 NC Trans-Golgi network protein
TGN38
Protein transport
U64689 4.3 NC Synaptotagmin interacting protein
zygin II
Protein transport
X12535 2.6 NC Rab7 Protein transport
AF052596 2.3 NC SNAP-23 Protein transport
M83676 2.1 NC Rab12 Protein transport
X13905 2.1 NC Ras-related rab1B protein Protein transport
AF019043 2.0 NC Dynamin-like protein (DLP1) Protein transport
X92097 2.0 NC Coated vesicle membrane protein Protein transport
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Gene no.
Ischemia
vs C CP vs C Gene product Function/description
AF072935 2.0 NC Rab5 Protein transport
AF097593 2.6 NC N-cadherin Adhesion molecule
L23088 2.1 1.5 P-selectin Adhesion molecule
AF097593 2.0 NC Testicular N-cadherin Adhesion molecule
M84488 2.5 1.5 Vascular cell adhesion molecule 1 Adhesion molecule
L20913 3.5 NC Vascular endothelial growth factor
form 3
Angiogenesis
X14232 2.5 NC Heparin-binding growth factor 1 Angiogenesis
M32167 2.3 NC Glioma-derived VEGF Angiogenesis
U93306 2.5 NC VEGF receptor-2/FLK-1 Angiogenesis
AF004811 4.0 NC Moesin Cytoskeletal
AF053768 3.2 NC Cortactin-binding protein CBP90 Cytoskeletal
AFFX-ba 2.8 NC Cytoplasmic -actin Cytoskeletal
AFFX 2.1 NC -Actin Cytoskeletal
S74572 3.0 NC Mg2-dependent protein
phosphatase 
Mg2-dependent phosphatase
S90449 3.0 NC Protein phosphatase 2C isoform Mg2-dependent phosphatase
AF071204 4.0 1.7 Kit ligand 1 precursor Stem cell factor
M11794 3.7 1.9 Metallothionein 2 and
metallothionein 1
Zinc homeostasis
AJ223083 12.1 NC Retinoic acid X receptor -1 Growth and development
M25350 3.2 NC cAMP phosphodiesterase (PDE4) s cAMP-mediated pathways
S77528 3.0 NC C/EBP-related transcription factor Apoptosis
AB000362 3.0 NC Cold-inducible RNA-binding protein Cold response
U77829 3.0 1.4 Gas-5 growth arrest homolog Growth arrest
X60212 2.8 NC Ribosomal protein L17 Translation
L13407 2.6 NC CaM kinase II  subunit Smooth muscle cell migration
U75920 2.5 1.6 APC-binding protein EB1 Cell cycle/microtubule binding
D45247 2.5 1.2 Proteasome subunit RCX Ubiquitin protein catabolism
D16308 2.3 1.6 Cyclin D2 Cell cycle
M58040 2.3 1.4 Transferrin receptor Iron transport
D90404 2.1 NC Cathepsin C Protease
Z83757 2.1 NC Growth hormone receptor Growth
X16043 2.1 NC Phosphatase 2A catalytic subunit  Phosphatase
D00092 2.0 NC 70-kd mitochondrial autoantigen Autoantigen
X77934 2.0 NC Amyloid precursor-like protein 2 Amyloid secretion
X99337 2.0 NC Glycoprotein 55 Glycoprotein
E05646 2.0 1.2 Hippocampal choline neuropeptide
HCNP
Phosphatidyl ethanolamine binding
U61373 2.0 NC Proteinase-activated receptor 2 G protein signal transduction
D84477 2.0 NC RhoA Ras-related/growth factor binding
M74494 2.0 1.2 Sodium/potassium ATPase -1
subunit
Na/K regulation
U50842 2.0 1.3 Ubiquitin ligase (Nedd4) Protein modification
Values represent fold change. Negative designates decrease. C, Control; CP, cardioplegia; NC, no change; CoA, coenzyme A; PDH, pyruvate dehydroge-
nase; ATP, adenosine triphosphate; DH, dehydrogenase; NADH, nicotinamide adenine dinucleotide; FA, fatty acid; UDP, uridine diphosphate; GTP, guanidine
triphosphate; BH4, tetrahydrobiopterin; MHC, major histocompatibility complex; IPC, ischemic preconditioning; MnSoD, manganese superoxide dismutase;
K(ATP), ATP-sensitive potassium channel; AT-BP1, antitrypsin binding protein 1; CELF, CUG-BP and ETR-3 like factor; SHARP-2, split- and hairy-related
protein-2; SNAP-23, synaptosomal-associated protein-23 kD; VEGF, vascular endothelial growth factor; cAMP, cyclic adenosine monophosphate; APC,
adenomatous polyposis coli; ATPase, adenosine triphosphatase.
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Gene no.
Ischemia
vs C CP vs C Gene product Function/description
Energy/metabolism
D87240 5.3 4.6 Fructose-6-phosphate 2-kinase Carbohydrate metabolism
AF047707 2.0 2.0 UDP-glucose:GlcT Lipid transport and metabolism
Immune/inflammatory
U17035 7.5 5.3 mob-1 Inflammatory/immune response
E02468 7.0 2.1 TNF Inflammatory/immune response
M80367 6.1 2.6 Guanylate-binding protein 2 Inflammatory/immune response
Y07704 5.3 2.8 BEST5 Inflammatory/immune response
M98820 4.3 4.0 Interleukin 1 Inflammatory/immune response
M34253 4.3 2.6 IRF-1 Inflammatory/immune response
D00403 4.0 3.0 Interleukin 1 Inflammatory/immune response
U68272 4.0 2.3 Interferon  receptor Inflammatory/immune response
U06434 3.7 2.6 MIP-1 Inflammatory/immune response
AF030358 3.7 2.3 Chemokine CX3C Inflammatory/immune response
X52711 3.5 4.0 Mx1 protein Inflammatory/immune response
X63594 3.5 2.6 RL/IF-1 Inflammatory/immune response
L00981 3.2 2.1 TNF-, TNF- Inflammatory/immune response
U22414 2.3 2.1 Inflammatory protein-1 Inflammatory/immune response
Cytoprotective-ischemia/IPC/stress
AF055714 4.6 2.3 Hypertension-reg vasc factor-1C-4 Stress response
L16764 4.6 4.9 Heat shock protein 70 (HSP70) Stress response
Transcription
U18314 3.0 2.3 Thymopoietin Transcription
AF015953 3.2 2.1 aryl hydrcrbn recept nucl translctr Transcription
L23148 9.8 3.5 Inhibitor of DNA binding 1 Transcription, angiogenesis
Other
L2552 7.0 2.6 E-selectin (ELAM-1) Adhesion molecule
D00913 4.3 2.1 Intercellular adhesion molecule 1 Adhesion molecule
X63722 3.2 2.0 Vascular cell adhesion molecule 1 Adhesion molecule
AJ011969 3.5 2.8 Growth differentiation factor 15 TGF- signaling
X57523 2.8 2.1 mtp1 Iron transport
AFFXbbm 2.0 2.0 7,8-Diamino-pelargonic acid Biotin synthesis proteins
U17604 3.0 2.1 Reticulon 1 Endocytosis
U78102 3.5 2.3 krox20 Growth and development
L26292 4.6 3.7 FSH-regulated protein Follicle-stimulating hormone related
AF036548 4.6 3.7 RGC-32 Response gene to complement 32
M26686 5.3 4.0 Carboxyl methyltransferase Protein modification
L19998 7.0 4.0 Minoxidil sulfotransferase Steroid metabolism
Values represent fold change. Negative designates decrease. C, Control; CP, cardioplegia; UDP, uridine diphosphate; TNF, tumor necrosis factor; BEST5,
bone-expressed sequence tag 5; IRF-1, interferon regulatory factor-1; MIP-1, macrophage inflammatory protein-1; RL/IF-1, nuclear factor of dappa light
chain gene enhancer in B-cells inhibitor, alpha; FSH, follicle stimulating hormone; RGC-23, response gene to complement 32.
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